Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Eine Phase -II -Studie zur Bewertung von NH102 auf Depressionen (NH102-21)

20. September 2026 aktualisiert von: Jiangsu Nhwa Pharmaceutical Co., Ltd.

Ein multizentrisches, randomisiertes, doppeltblindes, doppeltes Dummy-, Placebo-und aktiv kontrollierter klinischer Studie mit Dosis-Erklärungen zur Bewertung der Wirksamkeit und Sicherheit von NH102 bei der Behandlung von Depressionen

This study is a multicenter, randomized, double-blind, double-dummy, parallel-group, dose-finding Phase II clinical trial with placebo and active comparator duloxetine . It is designed to preliminarily assess the efficacy and safety of NH102 in patients with major depressive disorder and to provide the basis for the design of Phase III clinical trials.

Studienübersicht

Detaillierte Beschreibung

This trial consists of three periods: a screening period (up to 2 weeks), a double-blind treatment period (6 weeks), and a tapering-off period/safety follow-up (1 week). The screening period may last up to 14 days and a minimum of 1 day.

Baseline assessments will be conducted prior to randomization to confirm the eligibility of participants. A total of 240 patients with depression will be randomly assigned in a 1:1:1:1:1 ratio to three experimental drug groups (10 mg, 20 mg, and 30 mg), one active control group (duloxetine hydrochloride capsules 60 mg ), or one placebo group. The double-blind treatment period will last for 6 weeks, during which participants will take the assigned medications according to the specified dosing regimen and will be followed up at the end of weeks 1, 2, 4, and 6. After the treatment period, participants will enter a 1-week tapering-off period and will undergo safety follow-up at the end of week 7.

Studientyp

Interventionell

Einschreibung (Tatsächlich)

243

Phase

  • Phase 2

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienorte

    • Anhui
      • Hefei, Anhui, China, 230000
        • Anhui Mental Health Center
    • Beijing Municipality
      • Beijing, Beijing Municipality, China, 100096
        • Beijing Huilongguan Hospital
    • Chongqing Municipality
      • Chongqing, Chongqing Municipality, China, 400036
        • Chongqing Mental Health Center
    • Fujian
      • Xiamen, Fujian, China, 361012
        • Xiamen Xianyue Hospital
    • Guangdong
      • Guangzhou, Guangdong, China, 510370
        • The Affiliated Brain Hospital of Guangzhou Medical University
      • Shenzhen, Guangdong, China, 518118
        • Shenzhen Kangning Hospital
    • Hebei
      • Baoding, Hebei, China, 071000
        • Hebei Mental Health Hospital
    • Henan
      • Xinxiang, Henan, China, 453000
        • The Second Affiliated Hospital of Henan Medical University
      • Zhumadian, Henan, China, 463000
        • Zhumadian Second People's Hospital
    • Hunan
      • Changsha, Hunan, China, 410007
        • Hunan Second people's Hospital
    • Jiangsu
      • Suzhou, Jiangsu, China, 215000
        • Suzhou Guangji Hospital
      • Wuxi, Jiangsu, China, 214000
        • Wuxi Mental Health Center
    • Jiangxi
      • Nanchang, Jiangxi, China, 330038
        • Nanchang Mental Health Center
    • Jilin
      • Siping, Jilin, China, 136000
        • Jilin Provincial Neuropsychiatric Hospital
    • Shandong
      • Jinan, Shandong, China, 250014
        • Shongdong Mental Health Center
    • Shanghai Municipality
      • Shanghai, Shanghai Municipality, China, 200030
        • Shanghai Mental Health Center
    • Shanxi
      • Taiyuan, Shanxi, China, 030000
        • Frist Hospital of Shanxi Medical University
      • Xi’an, Shanxi, China, 710000
        • Xi'an Mental Health Center
    • Sichuan
      • Chengdu, Sichuan, China, 610072
        • Sichuan Provincial People's Hospital
      • Chengdu, Sichuan, China, 610000
        • The Fourth People's Hospital of Chengdu
    • Tianjin Municipality
      • Tianjin, Tianjin Municipality, China, 300000
        • Tianjin Anding Hospital
    • Zhejiang
      • Hangzhou, Zhejiang, China, 310003
        • Hangzhou Seventh People's Hospital
      • Huzhou, Zhejiang, China, 313000
        • Huzhou Third Municipal Hospital
      • Ningbo, Zhejiang, China, 315000
        • The Affiliated Kangning Hospital of Ningbo University

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

18 Jahre bis 65 Jahre (Erwachsene, Älterer Erwachsener)

Akzeptiert gesunde Freiwillige

Nein

Studienberechtigte Geschlechter

Alle

Beschreibung

Inclusion Criteria:

  • Male and female outpatients aged 18-65 years (inclusive).
  • Diagnosis of Major Depressive Disorder (MDD) according to DSM-5 criteria ( without psychotic features).
  • Hamilton Depression Rating Scale (HAM-D17) total score ≥ 22 at screening and baseline visits, with item 1 (depressed mood) score ≥ 2.
  • Clinical Global Impression-Severity (CGI-S) score ≥ 4 at screening and baseline.
  • Negative pregnancy test for women of childbearing potential.
  • Willingness to use effective contraception during the trial and for 3 months after the last dose.
  • Voluntary participation and signed informed consent.

Exclusion Criteria:

  • Duration of the current depressive episode in first-episode patients < 3 months.
  • Treatment-resistant depression (failure of ≥ 2 adequate antidepressant treatments).
  • Other psychiatric disorders (e.g., schizophrenia, bipolar disorder, anxiety disorders).
  • History of severe neurological diseases, epilepsy, or significant head trauma.
  • Unstable or severe cardiovascular, gastrointestinal, or endocrine diseases.
  • History of malignancy within the past 2 years.
  • History of increased intraocular pressure or untreated narrow-angle glaucoma.
  • Abnormal thyroid function not adequately controlled.
  • History of severe drug allergies or hypersensitivity to duloxetine or excipients.
  • Suicide attempt within the past year or significant suicide risk.
  • Substance abuse within the past year or positive at screening drug test.
  • Alcohol abuse (≥ 14 units/week) within the past year.
  • Previous treatment with duloxetine without adequate response.
  • Normative use of antidepressants within 2 weeks prior to screening.
  • Use of CYP2D6 or CYP1A2 potent inhibitors/inducers within 2 weeks prior to screening.
  • Participation in another clinical trial within the past 3 months.
  • Any condition deemed unsuitable by the investigator.

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Behandlung
  • Zuteilung: Zufällig
  • Interventionsmodell: Parallele Zuordnung
  • Maskierung: Vervierfachen

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Placebo-Komparator: Placebo

Matched dosing regimen.Twice daily for 6 weeks, followed by a 1-week tapering period.

Experimental: NH102 10 mg

5 mg twice daily over 6 weeks, followed by a 1-week tapering period.

10 mg twice daily over 6 weeks, followed by a 1-week tapering period.

15 mg twice daily over 6 weeks, followed by a 1-week tapering period.

Experimental: NH102 20mg

5 mg twice daily over 6 weeks, followed by a 1-week tapering period.

10 mg twice daily over 6 weeks, followed by a 1-week tapering period.

15 mg twice daily over 6 weeks, followed by a 1-week tapering period.

Experimental: NH102 30 mg

5 mg twice daily over 6 weeks, followed by a 1-week tapering period.

10 mg twice daily over 6 weeks, followed by a 1-week tapering period.

15 mg twice daily over 6 weeks, followed by a 1-week tapering period.

Aktiver Komparator: Dulloxetinhydrochlorid enterische Kapseln

30 mg twice daily for 6 weeks, followed by a 1-week tapering period.

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
17 items Hamilton Depression Scales (HAM-D17)
Zeitfenster: 6 Weeks

Changes from baseline in the 17 items Hamilton Depression Scales (HAM-D17) total score at the end of treatment.

HAM-D17 is a standardized, clinician-administered rating scale that assesses 17 items characteristically associated with major depression (symptoms such as depressed mood, guilty feelings, suicide, sleep disturbances, anxiety levels, and weight loss). Nine items are scored on a 3 point scale (0=none/absent to 2=most severe) and 8 items are scored on a 5 point scale (0=none/absent to 4=most severe) for a maximum total score of 50. Higher scores indicate a worse outcome.

6 Weeks

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
17 items Hamilton Depression Scales (HAM-D17)
Zeitfenster: Week 2 and 4

Changes from baseline in the 17 items Hamilton Depression Scales (HAM-D17) total score at Week 2 and 4.

HAM-D17 is a standardized, clinician-administered rating scale that assesses 17 items characteristically associated with major depression (symptoms such as depressed mood, guilty feelings, suicide, sleep disturbances, anxiety levels, and weight loss). Nine items are scored on a 3 point scale (0=none/absent to 2=most severe) and 8 items are scored on a 5 point scale (0=none/absent to 4=most severe) for a maximum total score of 50. Higher scores indicate a worse outcome.

Week 2 and 4
Montgomery- Åsberg Depression Rating Scale(MADRS)
Zeitfenster: 6 Weeks

Changes from baseline in the 10-items Montgomery- Åsberg Depression Scales (MADRS) total score at Week 2, Week 4 and the end of treatment.

MADRS is a standardized, clinician-administered rating scale that assesses 10 items characteristically associated with major depression. Items are rated on a scale of 0-6, for a total score range of 0 (low severity of depressive symptoms) to 60 (high severity of depressive symptoms).

6 Weeks
Clinical Global Impression-Improvement (CGI-I)
Zeitfenster: 6 Weeks

Changes from baseline in the CGI-I score at the end of treatment.

The Clinical Global Impression-Improvement (CGI-I) scale is a clinician-rated instrument designed to assess the overall improvement or worsening of a patient's condition relative to a baseline state. The following one query is rated on a seven-point scale: "Compared to the patient's condition at admission to the project, this patient's condition is: 1=very much improved since the initiation of treatment; 2=much improved; 3=minimally improved; 4=no change from baseline (the initiation of treatment); 5=minimally worse; 6= much worse; 7=very much worse since the initiation of treatment."

6 Weeks
Clinical Global Impression-Severity (CGI-S)
Zeitfenster: 6 Weeks

Changes from baseline in the Clinical Global Impression-Severity (CGI-S) score at the end of treatment.

The CGI-S asks the clinician one question: "Considering your total clinical experience with this particular population, how mentally ill is the patient at this time?" which is rated on the following seven-point scale: 1=normal, not at all ill; 2=borderline mentally ill; 3=mildly ill; 4=moderately ill; 5=markedly ill; 6=severely ill; 7=among the most extremely ill patients.

6 Weeks
Hamilton Anxiety Rating Scale (HAM-A)
Zeitfenster: 6 Weeks

Changes from baseline in the HAM-A total score at the end of treatment.

The Hamilton Anxiety Rating Scale (HAM-A) is a clinician-administered assessment tool to measure the severity of anxiety symptoms. It consists of 14 items, each evaluating a specific symptom of anxiety, such as anxious mood, tension, fears, and somatic complaints. Each item is scored on a scale from 0 (None) to 4 ( Very severe. grossly disabling ), with the total score ranging from a minimum of 0 to a maximum of 56. Higher scores indicate greater severity of anxiety symptoms, reflecting a worse clinical outcome.

6 Weeks
Dimensional Anhedonia Rating Scale (DARS)
Zeitfenster: 6 Weeks

Change from baseline in Dimensional Anhedonia Rating Scale (DARS) total score at the end of treatment.

The DARS is a self-report scale that measures anhedonia across the following 4 domains: hobbies/past-times, food/drinks, social activities, and sensory experiences. Within each domain, participants are required to provide at least two of their own examples of what they find rewarding. Subsequently, participants answer a set of standardized questions about desire, motivation, effort and consummatory pleasure for the examples provided. Responses were based on a 5-point Likert scale (Not at all=0; Slightly=1; Moderately=2; Mostly=3; Very Much=4), with the total score ranging from a minimum of 0 to a maximum of 68. A higher score reflects a better outcome.

6 Weeks

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Tatsächlich)

4. Dezember 2024

Primärer Abschluss (Tatsächlich)

30. Juli 2025

Studienabschluss (Tatsächlich)

12. September 2025

Studienanmeldedaten

Zuerst eingereicht

16. Februar 2025

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

19. Februar 2025

Zuerst gepostet (Tatsächlich)

24. Februar 2025

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

22. September 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

20. September 2026

Zuletzt verifiziert

1. November 2025

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Andere Studien-ID-Nummern

  • NH102-21

Plan für individuelle Teilnehmerdaten (IPD)

Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?

UNENTSCHIEDEN

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Nein

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .

Abonnieren